HK1171452A1 - Substituted pyrrolidine-2-carboxamides -2- - Google Patents
Substituted pyrrolidine-2-carboxamides -2-Info
- Publication number
- HK1171452A1 HK1171452A1 HK12112287.3A HK12112287A HK1171452A1 HK 1171452 A1 HK1171452 A1 HK 1171452A1 HK 12112287 A HK12112287 A HK 12112287A HK 1171452 A1 HK1171452 A1 HK 1171452A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- carboxamides
- substituted pyrrolidine
- pyrrolidine
- substituted
- Prior art date
Links
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical class NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/702,402 US8354444B2 (en) | 2008-09-18 | 2010-02-09 | Substituted pyrrolidine-2-carboxamides |
| PCT/EP2011/051619 WO2011098398A1 (en) | 2010-02-09 | 2011-02-04 | Substituted pyrrolidine-2-carboxamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1171452A1 true HK1171452A1 (en) | 2013-03-28 |
Family
ID=43608850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK12112287.3A HK1171452A1 (en) | 2010-02-09 | 2012-11-29 | Substituted pyrrolidine-2-carboxamides -2- |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8354444B2 (es) |
| EP (1) | EP2534132B1 (es) |
| JP (1) | JP5612710B2 (es) |
| KR (1) | KR101461298B1 (es) |
| CN (1) | CN102753522B (es) |
| AR (2) | AR080143A1 (es) |
| AU (1) | AU2011214506C1 (es) |
| BR (1) | BR112012019672B1 (es) |
| CA (1) | CA2788236C (es) |
| CL (1) | CL2012002189A1 (es) |
| CR (1) | CR20120410A (es) |
| CY (1) | CY1119049T1 (es) |
| DK (1) | DK2534132T3 (es) |
| EC (1) | ECSP12012083A (es) |
| ES (1) | ES2629439T3 (es) |
| HK (1) | HK1171452A1 (es) |
| HR (1) | HRP20170903T1 (es) |
| HU (1) | HUE034816T2 (es) |
| LT (1) | LT2534132T (es) |
| MX (1) | MX2012009186A (es) |
| MY (1) | MY165238A (es) |
| NZ (1) | NZ601422A (es) |
| PE (1) | PE20121532A1 (es) |
| PL (1) | PL2534132T3 (es) |
| PT (1) | PT2534132T (es) |
| RS (1) | RS56163B1 (es) |
| RU (1) | RU2564022C2 (es) |
| SG (1) | SG182763A1 (es) |
| SI (1) | SI2534132T1 (es) |
| TW (1) | TWI401243B (es) |
| UA (1) | UA107954C2 (es) |
| WO (1) | WO2011098398A1 (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7303676B2 (en) * | 2003-02-13 | 2007-12-04 | Zenon Technology Partnership | Supported biofilm apparatus and process |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| CN104945382B (zh) | 2009-10-14 | 2020-02-07 | 默沙东公司 | 提高p53活性的取代的哌啶和其用途 |
| US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| CA2829188C (en) | 2011-03-10 | 2016-10-18 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivatives |
| US8987274B2 (en) | 2011-10-28 | 2015-03-24 | Merck Sharp & Dohme Corp | Macrocycles that increase p53 activity and the uses thereof |
| WO2013096150A1 (en) | 2011-12-21 | 2013-06-27 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
| US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| US20130245089A1 (en) * | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
| US20140200255A1 (en) * | 2012-03-19 | 2014-07-17 | Brian Higgins | Method for administration |
| AU2013269798A1 (en) | 2012-05-30 | 2014-10-02 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| AU2013361694B2 (en) | 2012-12-20 | 2017-10-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
| NZ708272A (en) * | 2013-01-22 | 2020-07-31 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
| WO2014128094A1 (en) * | 2013-02-21 | 2014-08-28 | F. Hoffmann-La Roche Ag | Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide |
| US20140275562A1 (en) * | 2013-03-13 | 2014-09-18 | Dow Agrosciences Llc | Preparation of certain (substituted phenyl)-triazolyl-(substituted phenyl) molecules, and intermediates and insecticides related thereto |
| WO2014202492A1 (en) * | 2013-06-19 | 2014-12-24 | F. Hoffmann-La Roche Ag | Combination of ro5503781 and capecitabine for cancer therapy |
| KR20160009677A (ko) * | 2013-06-19 | 2016-01-26 | 에프. 호프만-라 로슈 아게 | 암 치료를 위한 ro5503781, 카페시타빈과 옥살리플라틴의 조합 |
| SG11201510654WA (en) * | 2013-06-24 | 2016-01-28 | Hoffmann La Roche | Stable intravenous formulation |
| JP6461126B2 (ja) | 2013-07-03 | 2019-01-30 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｍｄｍ２アンタゴニストを用いた患者のがん治療法をパーソナライズするためのｍｒｎａベースの遺伝子発現 |
| CA2926307C (en) | 2013-12-05 | 2021-11-16 | F. Hoffmann-La Roche Ag | Novel combination treatment for acute myeloid leukemia (aml) |
| US9657351B2 (en) | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
| CA2943571A1 (en) * | 2014-04-15 | 2015-10-22 | F. Hoffmann-La Roche Ag | Solid forms of a pharmaceutically active compound |
| SG10201913742TA (en) | 2014-04-17 | 2020-03-30 | Univ Michigan Regents | Mdm2 inhibitors and therapeutic methods using the same |
| JP6162646B2 (ja) * | 2014-05-27 | 2017-07-12 | 信越化学工業株式会社 | ３，５−ジメチルドデカン酸の製造方法 |
| CN106716131B (zh) * | 2014-10-10 | 2020-07-24 | 豪夫迈·罗氏有限公司 | Mdm2拮抗剂的癌症疗法的患者个性化方法 |
| DK3277677T3 (da) * | 2015-03-30 | 2021-05-25 | Mission Therapeutics Ltd | 1-cyano-pyrrolidinforbindelser som usp30-hæmmere |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
| KR102122469B1 (ko) | 2016-11-01 | 2020-06-12 | 주식회사 엘지화학 | 변성 공액디엔계 중합체 및 이의 제조방법 |
| PL3564208T3 (pl) | 2016-12-30 | 2022-03-21 | Oriental (Luzhou) Agrochemicals. Co., Ltd. | Sposób wytwarzania pochodnych kwasu 2-(cykloheksenyleno)malonowego i ich zastosowanie |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CN111065383A (zh) | 2017-07-11 | 2020-04-24 | 沃泰克斯药物股份有限公司 | 用作钠通道调节剂的羧酰胺 |
| CN108586195A (zh) * | 2017-12-27 | 2018-09-28 | 北京汇康博源医药科技有限公司 | 一种5-羟基-7，7-二甲基-2h-茚酮的制备方法 |
| WO2019213106A1 (en) | 2018-04-30 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Solid state forms of idasanutlin |
| CR20220316A (es) | 2019-12-06 | 2022-10-07 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio |
| WO2022256622A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| CN116459225B (zh) * | 2023-04-26 | 2023-11-10 | 东莞市金美济药业有限公司 | 一种艾拉戈克钠片及其制备工艺 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4732902A (en) | 1986-05-23 | 1988-03-22 | Hoffmann-La Roche Inc. | Pyrroloisoquinolinyl-dimethyloxoalkyl alkonoates and their use as antipsychotic agents |
| TW394760B (en) | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
| CA2298601A1 (en) | 1997-08-28 | 1999-03-11 | Pharmacia & Upjohn Company | Inhibitors of protein tyrosine phosphatase |
| US6482921B1 (en) | 1999-01-28 | 2002-11-19 | Essential Therapeutics, Inc. | Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use |
| US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| US6916833B2 (en) * | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
| CN1294120C (zh) * | 2003-10-21 | 2007-01-10 | 山东大学 | 吡咯烷类基质金属蛋白酶抑制剂及其应用 |
| US7550487B2 (en) * | 2004-03-26 | 2009-06-23 | Hoffmann-La Roche Inc. | Pyrrolidine-3,4-dicarboxamide derivatives |
| NZ561215A (en) * | 2005-02-22 | 2010-12-24 | Univ Michigan | Small molecule inhibitors of MDM2 and uses thereof |
| BRPI0609172A2 (pt) | 2005-02-22 | 2010-02-23 | Univ Michigan | inibidores de pequenas moléculas de mdm2 e usos destes |
| AU2006258300A1 (en) | 2005-06-17 | 2006-12-21 | Astrazeneca Ab | Thrombin inhibiting 2-oxo-1, 2, 5, 6-tetrahydropyridine derivatives |
| BRPI0713119A2 (pt) * | 2006-06-30 | 2012-04-17 | Schering Corp | piperidinas substituìdas que aumentam a atividade de p53 e os usos destas |
| CN101553219B (zh) | 2006-12-06 | 2013-04-24 | 塞诺菲-安万特股份有限公司 | 作为TAFIa抑制剂的脲和磺酰胺衍生物 |
| TW200911787A (en) | 2007-07-03 | 2009-03-16 | Astrazeneca Ab | New aza-bicyclohexane compounds useful as inhibitors of thrombin |
| JO2704B1 (en) * | 2007-09-21 | 2013-03-03 | جانسين فارماسوتيكا ان في | Interference inhibition factors between MD2 and B53 |
| US8134001B2 (en) * | 2007-12-14 | 2012-03-13 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| UA104002C2 (ru) | 2008-06-06 | 2013-12-25 | Санофи-Авентис | МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIa |
| AU2009263076B2 (en) | 2008-06-23 | 2012-07-26 | Astrazeneca Ab | New heterocyclic carboxamides for use as thrombin inhibitors |
| GB0811643D0 (en) * | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| JP5658157B2 (ja) * | 2008-09-18 | 2015-01-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換ピロリジン−２−カルボキサミド |
| US8017607B2 (en) * | 2009-10-14 | 2011-09-13 | Hoffmann-La Roche Inc. | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions |
-
2010
- 2010-02-09 US US12/702,402 patent/US8354444B2/en active Active
-
2011
- 2011-02-04 PL PL11702449T patent/PL2534132T3/pl unknown
- 2011-02-04 WO PCT/EP2011/051619 patent/WO2011098398A1/en active Application Filing
- 2011-02-04 DK DK11702449.7T patent/DK2534132T3/en active
- 2011-02-04 MX MX2012009186A patent/MX2012009186A/es active IP Right Grant
- 2011-02-04 AU AU2011214506A patent/AU2011214506C1/en active Active
- 2011-02-04 JP JP2012552343A patent/JP5612710B2/ja active Active
- 2011-02-04 ES ES11702449.7T patent/ES2629439T3/es active Active
- 2011-02-04 CA CA2788236A patent/CA2788236C/en active Active
- 2011-02-04 MY MYPI2012003543A patent/MY165238A/en unknown
- 2011-02-04 KR KR1020127023297A patent/KR101461298B1/ko active IP Right Grant
- 2011-02-04 RU RU2012138257/04A patent/RU2564022C2/ru active
- 2011-02-04 SI SI201131222T patent/SI2534132T1/sl unknown
- 2011-02-04 HU HUE11702449A patent/HUE034816T2/en unknown
- 2011-02-04 LT LTEP11702449.7T patent/LT2534132T/lt unknown
- 2011-02-04 PE PE2012001184A patent/PE20121532A1/es active IP Right Grant
- 2011-02-04 PT PT117024497T patent/PT2534132T/pt unknown
- 2011-02-04 NZ NZ601422A patent/NZ601422A/en unknown
- 2011-02-04 RS RS20170658A patent/RS56163B1/sr unknown
- 2011-02-04 CN CN2011800089274A patent/CN102753522B/zh active Active
- 2011-02-04 EP EP11702449.7A patent/EP2534132B1/en active Active
- 2011-02-04 BR BR112012019672-3A patent/BR112012019672B1/pt active IP Right Grant
- 2011-02-04 SG SG2012055752A patent/SG182763A1/en unknown
- 2011-02-07 AR ARP110100393A patent/AR080143A1/es active IP Right Grant
- 2011-02-08 TW TW100104166A patent/TWI401243B/zh active
- 2011-04-02 UA UAA201210421A patent/UA107954C2/ru unknown
-
2012
- 2012-08-03 EC ECSP12012083 patent/ECSP12012083A/es unknown
- 2012-08-07 CL CL2012002189A patent/CL2012002189A1/es unknown
- 2012-08-07 CR CR20120410A patent/CR20120410A/es unknown
- 2012-11-29 HK HK12112287.3A patent/HK1171452A1/xx unknown
-
2017
- 2017-06-13 HR HRP20170903TT patent/HRP20170903T1/hr unknown
- 2017-06-23 CY CY20171100673T patent/CY1119049T1/el unknown
-
2018
- 2018-12-13 AR ARP180103640A patent/AR114159A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP3607A (en) | Substituted imidazopyridazines | |
| DK3342786T3 (en) | Anti-dll3-antistof | |
| HK1171452A1 (en) | Substituted pyrrolidine-2-carboxamides -2- | |
| AP3107A (en) | 5-Alkynyl-pyrimidines | |
| EP2566479A4 (en) | AZA-INDAZOLES | |
| EP2640189A4 (en) | 3-deutero-pomalidomide | |
| DK3466977T3 (en) | Anti-vla-4-antistoffer | |
| EP2651505A4 (en) | ELECTROPORATION-INDUCED ELECTROSENSIBILIZATION | |
| EP2641891A4 (en) | PKC ACTIVATOR- | |
| HK1188782A1 (en) | Substituted sodium-1h-pyrazole-5-olate 1h--5- | |
| AU4937P (en) | FlatinsulGL Myoporum insulare | |
| AU4931P (en) | FlatwaxDarkGL Chamelaucium uncinatum | |
| AU4932P (en) | FlatwaxpinkGL Chamelaucium uncinatum | |
| AU4822P (en) | FlatwaxwhiteGL Chamelaucium uncinatum | |
| AU2010194V (en) | CalpenGL Calothamnus quadrifidus | |
| AU2010165V (en) | Silversunrise Conostylis candicans | |
| GB201001976D0 (en) | Clipperon | |
| GB201000799D0 (en) | 2velcrose | |
| GB201000765D0 (en) | Koolkilt | |
| GB201000706D0 (en) | Kilthanger | |
| GB201000547D0 (en) | Jurasic | |
| GB201000426D0 (en) | Earbling | |
| GB201000203D0 (en) | Formits | |
| GB201000246D0 (en) | Head-kase | |
| GB201000262D0 (en) | Flexishaft |